KPV

KPV (Lys-Pro-Val) is the anti-inflammatory C-terminal tripeptide of α-melanocyte-stimulating hormone (α-MSH), researched for gut inflammation, skin barrier repair, and broad NF-κB-mediated inflammatory pathway inhibition. It is one of the better-studied small anti-inflammatory peptides with preclinical and early clinical evidence in inflammatory bowel disease contexts. Important regulatory update: On April 22, 2026 the FDA removed KPV from its Category 2 bulk drug substances list because the nomination had been withdrawn by the nominators, and at the July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting the committee voted 8–6–1 to recommend KPV for the 503A compounding bulks list — an advisory recommendation that FDA scientific staff opposed and the agency has not finalized.

Sources: FDA Announces Removal of 12 Peptides from Category 2 (nominations withdrawn by the nominators) and Schedules PCAC Meetings, Orrick (legal analysis of the FDA notice), via Orrick Insights; PCAC July 23–24 2026 meeting outcome, FDA PCAC, via Buchanan Ingersoll / Clinical Peptide / NCPA / AJMC

What is KPV and how does the α-MSH-derived anti-inflammatory mechanism work?

KPV is the C-terminal tripeptide of α-MSH (alpha-melanocyte-stimulating hormone), retaining the anti-inflammatory activity of the parent hormone while losing the melanocortin receptor binding responsible for pigmentation effects. KPV inhibits NF-κB signaling, reduces pro-inflammatory cytokine production, and modulates immune cell function — particularly in epithelial tissues. The compound's small size (3 amino acids) supports oral bioavailability for gut-targeted indications.

Evidence level: preclinical extensive (inflammatory bowel disease, skin inflammation, oral biology); limited human clinical

What does the research show for KPV?

Preclinical studies have demonstrated reduced colonic inflammation in IBD models, accelerated skin barrier repair in wound healing models, and reduced periodontal inflammation in dental research contexts. No human clinical trials of KPV have been published as of August 2026; the evidence base is preclinical. In murine models, the melanocortin-derived tripeptide KPV produced significant anti-inflammatory effects in two models of colitis, acting through PepT1-mediated uptake into intestinal epithelial and immune cells to reduce intestinal inflammation. Use in clinical or complementary-care settings is off-label and anecdotal, not trial evidence.

Sources: Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease, Kannengiesser K., Maaser C., Heidemann J., et al., Inflammatory Bowel Diseases, 2008; PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation, Dalmasso G., Charrier-Hisamuddin L., Nguyen H.T., et al., Gastroenterology, 2008 · Evidence level: preclinical extensive across inflammation models; human clinical limited

How does KPV compare to other anti-inflammatory peptides?

KPV operates through NF-κB inhibition at very small molecular size, distinguishing it from longer anti-inflammatory peptides like BPC-157 (which acts through different mechanisms — angiogenesis, growth factor signaling) and from broader immune modulators like Thymosin Alpha-1.

What are the documented side effects of KPV?

KPV's safety profile in preclinical studies and available human research use has been favorable — the most common report is mild injection-site reactions (for injectable use) or no notable effects (for oral/topical use). The small size and α-MSH-derived origin support a low side-effect burden. Long-term safety at sustained research-use dosing is not characterized at Western RCT standards.

Evidence level: preclinical safety; human long-term unestablished

What is the regulatory status of KPV?

KPV is not approved for any medical indication anywhere in the world as of August 2026. On April 22, 2026, KPV was removed from the FDA's Category 2 bulk substances list and is scheduled for Pharmacy Compounding Advisory Committee (PCAC) review in July 2026. Removal from Category 2 does not authorize compounding — formal Category 1 inclusion or 503A bulks list addition remains pending PCAC determination. Current status in FDA peptide regulation 2025–2026 timeline.

Why does KPV vendor verification matter?

KPV's short tripeptide structure (Lys-Pro-Val) makes synthesis straightforward and broadly available, but identity verification still matters — and the small molecular weight (~342 Da) requires mass spectrometry confirmation. Independent HPLC purity testing is the standard quality signal. Guidance in how-to-test-peptides hub.

How does Peptigrity verify KPV vendors?

Peptigrity collects independent third-party Certificates of Analysis for KPV from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. Methodology in how we calculate trust scores.

Frequently asked questions

What does KPV do?

KPV is researched for anti-inflammatory effects through NF-κB pathway inhibition, with preclinical evidence in inflammatory bowel disease, skin barrier repair, and oral inflammation. Human clinical evidence is more limited than the preclinical base.

Is KPV legal to purchase?

KPV is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption. The April 2026 Category 2 removal and the July 2026 PCAC 8–6–1 recommendation are steps toward a possible future compounding pathway, but neither authorizes compounding today. Country breakdown in peptide legal status guide.

When will the FDA decide on KPV?

KPV is scheduled for Pharmacy Compounding Advisory Committee (PCAC) review in July 2026. Removal from Category 2 in April 2026 was a procedural step; formal authorization for compounding pharmacy production remains pending PCAC determination. Track developments in FDA peptide regulation 2025–2026 timeline.

Can KPV be taken orally?

KPV's small size (three amino acids) and its uptake by the intestinal peptide transporter PepT1 give it more plausible oral/gut-targeted activity than longer peptides — in a mouse model, orally administered KPV reduced colitis. That evidence is preclinical; there are no human trials establishing an oral dose or effect. Injectable, oral, and topical formulations are all represented in research-grade vendor markets.

Source: PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation, Dalmasso G., Charrier-Hisamuddin L., Nguyen H.T., et al., Gastroenterology, 2008

How can I verify a KPV vendor is selling real product?

Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation (expected MW ~342 Da). COA interpretation in red flags in peptide certificates of analysis.

Does Peptigrity recommend a KPV dose?

No. KPV is not approved for human consumption and Peptigrity is an independent review platform, not a medical authority. Research-use dosing in community protocols varies by route. Anyone considering use should consult a licensed physician.

This section is for educational and informational purposes only and does not constitute medical advice. KPV is not approved by the FDA or any major Western regulator for human use, though it was removed from Category 2 of the FDA 503A bulk substances list in April 2026 and is scheduled for PCAC review in July 2026. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.